Sysmex (6869.T) Aandeel Koers
Sysmex Koers
De omzet is de afgelopen 19 jaar met 8,8% per jaar gegroeid tot 500,01 Miljard JPY. De winst per aandeel is de afgelopen 19 jaar met 7,5% per jaar gegroeid. De nettowinstmarge van Sysmex ligt op 7,1% en is ten opzichte van 12,1% enkele jaren eerder gedaald. Sysmex biedt momenteel een dividendrendement van circa 2,85%. De uitkeringsratio ligt rond 39% van de winst. Het dividend is de afgelopen 19 jaar met 15,9% per jaar gegroeid. Analisten hanteren een mediaan koersdoel van 2.320,50 JPY — dat impliceert 20,0% boven de huidige koers. Van de 21 analisten geven 16 het aandeel een koopadvies — per saldo een Kopen-consensus.
Sysmex aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Sysmex bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Sysmex
Sysmex Corp is a leading healthcare company specializing in diagnostic testing equipment and technologies. The business model of Sysmex Corp revolves around the design, development, and manufacture of innovative testing systems for clinical laboratories and healthcare institutions. With a strong focus on hematological analysis and hemostasis, Sysmex Corp provides highly accurate and reliable diagnostic solutions to support disease detection, monitoring, and treatment. By leveraging advanced technologies and automation, the company enables efficient and precise diagnostic processes, ultimately contributing to better patient outcomes. Sysmex Corp's business model centers on delivering cutting-edge diagnostic solutions that empower healthcare professionals with the tools they need for accurate and timely diagnoses.
Sysmex Corp is primarily active in the healthcare and medical technology industries.
The main competitors of Sysmex Corp in the market include Abbott Laboratories, Siemens Healthineers, and Becton, Dickinson and Company (BD).
Sysmex Corp is a renowned healthcare company specializing in diagnostic solutions for medical organizations. Founded in 1968, Sysmex Corp has since achieved global recognition for its advanced technologies and commitment to improving medical diagnoses and treatments. The company offers a wide range of innovative products, including automated clinical laboratory systems, reagents, and software. Sysmex Corp has established itself as a leader in the field of blood and urinalysis testing, leveraging cutting-edge research and partnerships to enhance patient care. With a rich history spanning several decades, Sysmex Corp continues to revolutionize the healthcare industry with its strategic advancements and dedication to improving medical outcomes worldwide.
Sysmex Corp has achieved several significant milestones throughout its history. Some of these achievements include the development of the world's first automated blood coagulation analyzer, the introduction of the first fully automated urine sediment analyzer, and the establishment of international subsidiaries to expand its global presence. Sysmex Corp has also made advancements in the field of hematology, with the production of automated blood cell analyzers that provide accurate and efficient results. Additionally, the company has received recognition for its contributions to healthcare, such as the Japan Medical Device Excellence Award. Overall, Sysmex Corp's commitment to innovation and quality has led to various notable milestones in the medical technology industry.
Sysmex Corp is primarily present in various countries and regions across the globe. Some of the key markets where Sysmex Corp has a significant presence include Japan, the company's home country, where it is headquartered. Sysmex Corp also has a strong foothold in the Asia-Pacific region, particularly in China, South Korea, and India. Furthermore, Sysmex Corp has expanded its operations and established a notable presence in North America, primarily in the United States. Additionally, Sysmex Corp has a growing presence in Europe, with key markets such as Germany, France, and the United Kingdom.
Sysmex Corp represents values of integrity, innovation, and collaboration. With a strong corporate philosophy that revolves around contributing to the advancement of healthcare, Sysmex Corp is committed to providing reliable and efficient diagnostic solutions. The company prioritizes sustainable growth, social responsibility, and customer satisfaction. Through their cutting-edge technologies and solutions in the field of laboratory testing, Sysmex Corp aims to improve patient outcomes and enhance overall healthcare globally. With their dedication to excellence and continuous improvement, Sysmex Corp has established itself as a trusted leader in the healthcare industry.
Analisten hanteren momenteel een gemiddeld koersdoel van 2.391,26 JPY voor het aandeel Sysmex (mediaan: 2.320,50 JPY), oftewel +23,7 % ten opzichte van de laatste koers. De consensus is gebaseerd op 21 analistenratings.
21 analisten beoordelen het aandeel Sysmex momenteel: 16 adviseren kopen, 5 houden en 0 verkopen.
Omgezet tegen de huidige wisselkoers noteert het aandeel Sysmex op 10,98 EUR (1.933,00 JPY).
Het aandeel Sysmex (6869.T) is genoteerd aan 4 beurzen, waaronder: Tokio (JPX) (6869.T), Frankfurt (0YX.F), München (0YX.MU).
Sysmex Corp is a Japanese manufacturer of medical diagnostic devices and systems. The company is a global leader in the development and production of hematology and urine analysis devices, coagulation analysis devices, immunoassay systems, cell imaging devices, and laboratory automation solutions. The company is divided into three business segments: Diagnostic Business, Life Science Business, and IT Business. The Diagnostic Business focuses on the development and production of hematology and urine analysis devices and coagulation analysis devices, which are used in various medical fields such as hematology, oncology, pediatrics, and intensive care medicine. The Life Science Business includes immunoassay systems, cell imaging devices, and laboratory automation solutions, which are used in research and development, diagnostics, and drug development. The IT Business provides IT-based solutions for the medical fields served by the other business segments, aiming to efficiently collect and process data. Sysmex Corp is known for its research and development efforts, as well as its manufacturing capabilities, and it has established itself as an important player in the global healthcare industry. The company has a strong presence in international markets, with branches in over 190 countries. Sysmex Corp has partnerships with leading companies in the medical and pharmaceutical industries, allowing it to further strengthen and expand its position in the market. The company has a customer-oriented approach and strives to meet the needs of its clients. Overall, Sysmex Corp has revolutionized and modernized various medical fields with its unique products and services, making a significant contribution to the global healthcare industry.
De omzet van Sysmex bedraagt 500,01 Miljard JPY. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De winst van Sysmex bedraagt 35,46 Miljard JPY. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Sysmex bedraagt momenteel 33,43. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Sysmex-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Sysmex bedraagt momenteel 2,37. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Sysmex-aandeel.
De Eulerpool Kwaliteitsscore voor Sysmex is 6/10.
De ISIN van Sysmex is JP3351100007. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Sysmex is 897966. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Sysmex is 6869.T. Onder dit beurstickersymbool wordt het Sysmex-aandeel op de beurs verhandeld.
Sysmex aandeel
Sysmex Ticker
Sysmex FIGI
Alle fundamentals en diepgaande analyse van Sysmex
Onze aandelenanalyse van het Sysmex-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Sysmex. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: